Rhythm Pharmaceuticals secures FDA approval for sNDA for IMCIVREE to treat BBS
With this FDA approval, IMCIVREE is indicated for chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity due to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.